In this respect, in human metastatic castration-resistant prostate cancer it has been described that the differential response to PARPi between BRCA1 and BRCA2 mutated cancers was due to the concomitant presence of a TP53 mutation as well as the allelic representation [39, 40]. This evidence concerns the gene BRCA1 and prostate cancer.